Rayner has secured Medical Device and Human Tissue Advisory Committee acceptance and Prostheses List (PL) reimbursement for RayOne Galaxy, effective 1 March 2026.

RayOne Galaxy is the world’s first spiral intraocular lens (IOL). Developed with artificial intelligence, its unique non-diffractive spiral optic delivers a smooth and continuous full range of vision with minimised dysphotopsia and 0% loss of transmitted light.1

Since its global launch in January 2025, RayOne Galaxy has demonstrated strong international clinical adoption, with more than 90,000 lenses shipped worldwide. And, according to Rayner, surgeons across multiple international markets have reported consistent refractive predictability, broad functional visual range, and high patient satisfaction in everyday clinical practice.

Real-world experience presented at the European Society of Cataract and Retinal Surgeons (ESCRS), reinforced confidence in the technology.2 In parallel, Rayner stated that a United States clinical study conducted under a Food and Drug Administration (FDA)-approved Investigational Device Exemption (IDE) confirmed favourable safety and effectiveness outcomes, with regulatory review in the United States ongoing.3

Now, with PL reimbursement confirmed, privately insured cataract patients can access the Galaxy spiral lens without the additional out-of-pocket costs typically associated with non-listed lenses – an important step forward in expanding access to this advanced presbyopia-correcting technology.

Lisa Farquhar, Rayner’s Country Manager for Australia and New Zealand, said the Galaxy delivers “a continuous range of vision without the trade-offs patients get with diffractive trifocal lenses”.

“We are proud that this innovative technology will now be accessible to any privately insured patient in Australia, helping surgeons offer truly premium outcomes to more people than ever before,” she said.

References available at mivision.com.au.